Hans Keirstead

Veteran SaaS Sales Executive Brett Keirstead to Lead Growth Initiatives for Chief Outsiders’ Clients

Retrieved on: 
Thursday, February 16, 2023
Knowledge, Software as a service, CP/M, Clemson University, Fraction, Mentorship, CMOS, Hans Keirstead, Sense, Knowledge market, MESA, Growth, IAP, Management, Accounting, Science

Recently, Keirstead joined Chief Outsiders’ team of more than 125 Fractional Chief Sales Officers (CSOs) and Fractional Chief Marketing Officers (CMOs).

Key Points: 
  • Recently, Keirstead joined Chief Outsiders’ team of more than 125 Fractional Chief Sales Officers (CSOs) and Fractional Chief Marketing Officers (CMOs).
  • “Brett expertly leads client retention, engagement and growth initiatives, and works with C-level executives to scope and secure complex, profitable projects,” said Karen Hayward, Managing Partner, Chief Outsiders.
  • At Chief Outsiders, Keirstead works with CEOs of early-stage and mid-market SaaS companies to accelerate sales growth .
  • For example, prior to joining Chief Outsiders, he achieved 250% revenue growth in 4 years with 300% growth in recurring SaaS revenue as SVP Sales and Operations at Knowledge Marketing.

AIVITA Biomedical CEO Hans Keirstead Receives 2021 Global Humanitarian Award

Retrieved on: 
Thursday, March 4, 2021
Medical research, Medicine, Hans Keirstead, Health sciences, COVID-19 vaccine, Vaccine, Medical specialties

IRVINE, Calif., March 4, 2021 /PRNewswire/ --AIVITA Biomedical, a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, today announced that Hans Keirstead, Ph.D., chairman and chief executive officer, will receive Mission Plasticos' 2021 Global Humanitarian Award during its Celebration of Global Friendships Gala on September 11.

Key Points: 
  • IRVINE, Calif., March 4, 2021 /PRNewswire/ --AIVITA Biomedical, a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, today announced that Hans Keirstead, Ph.D., chairman and chief executive officer, will receive Mission Plasticos' 2021 Global Humanitarian Award during its Celebration of Global Friendships Gala on September 11.
  • Dr. Keirstead was selected as the Global Humanitarian Award recipient based on his life-long efforts to decrease human suffering, including his current efforts in developing a unique COVID-19 vaccine program that if effective can be scaled rapidly to meet global need for the ongoing pandemic.
  • "We are honored to present this year's Global Humanitarian award to Hans in recognition of the incredible strides made by AIVITA as well as his ongoing support on our board of directors," said Susan Williamson, executive director of Mission Plasticos.
  • AIVITA Biomedical, Inc. is a personalized vaccine company evaluating vaccines for prevention of COVID-19 infection and treatment of cancer.

AIVITA Biomedical CEO Hans Keirstead Named to “20 in 2020” by Consulate General of Canada for Contributions to COVID-19 Research

Retrieved on: 
Thursday, July 2, 2020
Oncology, Health, Infectious diseases, Clinical trials, Research, Science, Biotechnology, Hans Keirstead

AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, announced that Hans Keirstead, Ph.D., chairman and chief executive officer, has been named to the 20 in 2020 by the Consulate General of Canada.

Key Points: 
  • AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, announced that Hans Keirstead, Ph.D., chairman and chief executive officer, has been named to the 20 in 2020 by the Consulate General of Canada.
  • I am honored to be recognized by the Canadian Consulate General alongside others who are working to address the pandemic in various areas of society.
  • Before AIVITA, he founded and served as chief executive officer of California Stem Cell, and founded and served as chief executive officer of Ability Biomedical.
  • Dr. Keirstead was also a professor at the University of California at Irvine, where he founded and directed the Sue and Bill Gross Stem Cell Research Center.

AIVITA Biomedical to Present at 2019 BIO International Convention Detailing New Clinical Data from Phase 2 Glioblastoma Trial

Retrieved on: 
Friday, May 31, 2019
Health, Clinical research, Medical research, Pharmaceutical industry, Clinical trial, Design of experiments, Drug discovery, Hans Keirstead

AIVITA CEO Dr. Hans Keirstead will deliver a corporate presentation highlighting the company's clinical and commercial programs.

Key Points: 
  • AIVITA CEO Dr. Hans Keirstead will deliver a corporate presentation highlighting the company's clinical and commercial programs.
  • The BIO International Convention is an annual event hosting more than 16,000 attendees from around the globe seeking opportunities in partnering, education, and networking with global biotech and pharma leaders.
  • Details of the company presentation are as follows:
    In his presentation Dr. Keirstead will highlight new predictive efficacy clinical efficacy data from AIVITA's ongoing 8-center Phase 2 immunotherapy clinical trial in patients with glioblastoma.
  • AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines.